Stay updated with breaking news from Jack Cuzick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Measuring serum hormone concentrations in postmenopausal women at high risk for developing BC may help identify those most likely to benefit from preventive treatment with an aromatase inhibitor.
<p>Research led by Queen Mary University of London’s Wolfson Institute of Population Health has found that hormone levels, measured through blood tests, are an important indicator of whether women will benefit from recently licensed medication for the prevention of breast cancer.</p>
This 4p-a-day pill has been hailed as a game-changer. But the frequent side effects mean women are already giving it up in their droves.
Medicines and Healthcare Products Regulatory Agency in the United Kingdom has recently approved the use of anastrozole, an aromatase inhibitor, for the reduction of breast cancer risk in women after menopause. How does it work?
An oral medicine called anastrozole has been approved by the UK's drug regulatory agency for reducing the risk of breast cancer in post-menopausal women at moderate-to-high risk of the condition